Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
- 98
New York, New York--(Newsfile Corp. - December 30, 2024) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
If you are a long-term IMVT stockholder please contact Justin Kuehn, Esq. here, by email at [email protected], or call (833) 672-0814. The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235599
- EQS-News: Alzchem Group AG: Bekanntmachung nach Art. 5 der Verordnung (EU) 596/2014 und Art. 2 Abs. 1 der Delegierten Verordnung (EU) 2016/1052 - 5. Zwischenmeldung
- EQS-News: Erfolgreicher Verlauf der ordentlichen Hauptversammlung der ARI Motors Industries SE
- EQS-News: ILI.DIGITAL eröffnet Standort in Lissabon und vernetzt internationale Teams
- Glarner Kantonalbank stellt Weichen für den weiteren Erfolg im EVV-Geschäft
- Die EWE NETZ GmbH hat sich für OverIT entschieden, um ihre Prozesse zur Personaleinsatzplanung zu erneuern
- EQS-News: Bilfinger SE: Bekanntmachung gemäß Art. 5 Abs. 1 der Verordnung (EU) Nr. 596/2014 und Art. 2 Abs. 1 der Delegierten Verordnung (EU) Nr. 2016/1052